Capmatinib launch date

Capmatinibon2020year5month6Approved by the U.S.FDA for listing, capmatinib will be launched in China in July of 2021. Capmatinib is a kinase inhibitor targeting the c-Met receptor tyrosine kinase and is indicated for the treatment of Met exon 14 skipped non-small cell lung cancer.

A patient treated withcapmatinib developed fatalILD/pneumonitis. 4.8%of patients receiving capmatinib with geometrymono-1 developed ILD/pneumonitis, 1.9% patients developed grade ILD/ pneumonia, and 1 patient died (0.3%). Nine patients (2.4%) discontinued Taibida due to ILD/pneumonitis. The median time to onset of grade 3 or higher ILD/pneumonia was 1.8 months (range : 0.2 months to 1.7 years). Monitor for new or worsening symptoms of ILD/pneumonia (e.g., difficulty breathing, cough, fever). For patients with suspected ILD/pneumonia, discontinue this product immediately, or permanently if no other potential causes of ILD/pneumonia are found. Hepatotoxicity occurred in patients receivingcapmatinib. 15%Accept geometric shapesmono-1's Capmatinib-treated patients experienced an increase in alanine aminotransferase (ALT) /aspartate aminotransferase (AST). 7%of patients had ALT/AST grade 3 or 4 grade elevation. Three patients (0.8%) discontinued capmatinib due to ALT/AST elevations. The median time to onset of grade 3 or higher ALT/AST elevations was 1.8 months (range: 0.5 to 46.4 months). Before starting capmatinib, monitor liver function tests (including ALT,AST and total bilirubin), then monitor monthly or as clinically indicated, with more frequent testing in patients with elevated transaminases or bilirubin. Depending on the severity of the adverse reaction, discontinue use, reduce the dose, or permanently discontinue capmatinib. There are officially marketed generic drugs in Laos, and each box costs about 3 about 3,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.